Home Companies Oxford Nanopore

Oxford Nanopore

Sequencing and COVID-19: From Genomic Epidemiology to Host Response
Companies

Sequencing and COVID-19: From Genomic Epidemiology to Host Response

Chris Anderson -
0
Using Nanopore Sequencing to Study Full-Length Transcripts and Splicing Isoforms
Companies

Using Nanopore Sequencing to Study Full-Length Transcripts and Splicing Isoforms

Kathy Vuksanaj -
0
New Tools for Studying Genetic Variation in Cancer
Companies

New Tools for Studying Genetic Variation in Cancer

Kathy Vuksanaj -
0
Clinical Research in a Real-Time Sequencing Age
eBooks

Clinical Research in a Real-Time Sequencing Age

Kathy Vuksanaj -
0
From Bench to Clinic—The Potential of New Sequencing Tools
Companies

From Bench to Clinic—The Potential of New Sequencing Tools

Kathy Vuksanaj -
0
Going Deeper into Long Reads: Oxford Nanopore Licenses CRISPR-Cas9 IP from Caribou
Companies

Going Deeper into Long Reads: Oxford Nanopore Licenses CRISPR-Cas9 IP from Caribou

Julianna LeMieux, Ph.D. -
0
Oxford Nanopore Opens Factory to Meet Demand for MinION, Other DNA/RNA Sequencers
Biomarkers

Oxford Nanopore Opens Factory to Meet Demand for MinION, Other DNA/RNA Sequencers

Alex Philippidis -
0
12Page 1 of 2

Trending

Cancer-Killing Oncolytic Virus Against Solid Tumors Enters Phase 1 Trial

Cancer-Killing Oncolytic Virus Against Solid Tumors Enters Phase 1 Trial

Novel Method May Predict HCC Immunotherapy Response

Novel Method May Predict HCC Immunotherapy Response

FAP-Targeting Imaging Tracker Prepares for Phase 1 Brain Cancer Trial

FAP-Targeting Imaging Tracker Prepares for Phase 1 Brain Cancer Trial

Immunotherapy Reduces Bladder Cancer Recurrence

Immunotherapy Reduces Bladder Cancer Recurrence

Copyright © 2022 Genetic Engineering & Biotechnology News. All Rights Reserved.